GlassScriptPhysician profile
Steve John Hamberis
NPI 1891739439
$18,901.84
in general payments reported to CMS, 2019-2025
65 companies · $2,517 in 2025
The $2,517 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,863 · 2020: $1,306 · 2021: $3,189 · 2022: $2,925 · 2023: $3,426 · 2024: $2,677 · 2025: $2,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,619.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,338.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,257.59 | 2019-2025 | |
| Lilly USA, LLC | $1,518.57 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $1,234.22 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,123.93 | 2019-2025 | |
| Amgen INC. | $806.33 | 2019-2025 | Otezla, Repatha, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $739.82 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $625.72 | 2019-2025 | Rexulti, Nuedexta |
| Janssen Pharmaceuticals, INC | $605.04 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $561.90 | 2019-2025 | Xifaxan |
| Exact Sciences Corporation | $524.85 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $494.96 | 2020-2021 | |
| Esperion Therapeutics, INC. | $431.70 | 2020-2025 | Nexletol |
| Glaxosmithkline, LLC. | $414.64 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $396.38 | 2019-2022 |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Hamberis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.